What question did this study set out to answer?

To determine if a multimodal strategy using LVGLS, LASr, and hs-TnI can predict early cardiotoxicity from anthracycline chemotherapy.

April 14, 2026Journal of Cardiovascular ImagingOpen Access

A multimodal approach to early detection of anthracycline-induced cardiotoxicity: complementary roles of left ventricular global longitudinal strain, left atrial reservoir strain, and high-sensitivity troponin I

Q: What are the key findings of this study?

A multimodal surveillance strategy integrating left ventricular global longitudinal strain, left atrial reservoir strain, and high-sensitivity troponin I demonstrated excellent discrimination for early anthracycline-induced cardiotoxicity (AUC 0.979).

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Breast cancer treated with anthracycline-based chemotherapy (n=50). Intervention: Multimodal surveillance strategy (LVGLS, LASr, and hs-TnI) vs. Single-parameter assessment (LVGLS alone). Primary outcome: Early anthracycline-induced cardiotoxicity (> 10% reduction in LVEF to < 53% at 1 month) (AUC 0.979, 95% CI 0.954-1.000, p=0.003).

View Full Paper

Ask AI

Bookmark

Key result

Multimodal surveillance using LVGLS, LASr, and hs-TnI detects early anthracycline-induced cardiotoxicity with AUC ~0.98.

AUC 0.979
95% CI 0.954-1.000
P=0.003
n=50

Why the study?

Anthracycline chemotherapy causes dose-dependent cardiotoxicity, making early identification of subclinical myocardial injury crucial to prevent irreversible dysfunction.

Does a multimodal surveillance strategy integrating LVGLS, LASr, and hs-TnI predict early anthracycline-induced cardiotoxicity in female breast cancer patients?

Population

50 female breast cancer patients receiving anthracycline-based chemotherapy

Comparison

Multimodal surveillance integrating LVGLS, LASr, and hs-TnI vs baseline

Design

Retrospective cohort study

Follow-up

1 month after chemotherapy

Authors

AKAhmet Ferhat Kaya MÖMehmet Özbek

Discussion

Member takes

Overview

May improve early anthracycline cardiotoxicity detection via multimodal surveillance; extends prior evidence but remains hypothesis-generating pending validation.

Key Points

To determine if a multimodal strategy using LVGLS, LASr, and hs-TnI can predict early cardiotoxicity from anthracycline chemotherapy.
Retrospective cohort study with 50 female breast cancer patients
Echocardiography and biomarkers assessed at baseline and one month post-chemotherapy
Cardiotoxicity defined as >10% reduction in LVEF to <53%
Cardiotoxicity occurred in 15 patients (30%)
All measured parameters (LVGLS, LASr, hs-TnI) significantly changed (P < 0.001)
hs-TnI demonstrated the highest ability to discriminate cardiotoxicity (AUC 0.940)

Study Design

Type

Cohort (n=50)

Multicenter

Structured PICO

Does a multimodal surveillance strategy integrating LVGLS, LASr, and hs-TnI predict early anthracycline-induced cardiotoxicity in female breast cancer patients?

Population

50 female breast cancer patients treated with anthracycline-based chemotherapy, mean age 49.3 ± 8.5 years.

Intervention

Multimodal surveillance strategy integrating left ventricular global longitudinal strain (LVGLS), left atrial reservoir strain (LASr), and high-sensitivity troponin I (hs-TnI) assessed at baseline and 1 month after chemotherapy.

Outcome

Early anthracycline-induced cardiotoxicity (defined as a > 10% reduction in LVEF to < 53%) at 1 month after chemotherapy.surrogate

Main Result

Effect estimate: AUC 0.979 (95% CI 0.954-1.000)

p-value: p=0.003

A multimodal approach combining LVGLS, LASr, and hs-TnI effectively predicts early anthracycline-induced cardiotoxicity in breast cancer patients, with hs-TnI demonstrating the highest discriminative ability.

Limitations

Small sample size and limited number of outcome events (n = 15) increasing the risk of model overfitting
No external validation cohort was included
Cardiotoxicity was defined based on a single 1-month follow-up echocardiographic assessment without serial confirmation
Follow-up was limited to the early post-chemotherapy period
Left atrial strain was derived from standard left ventricular-focused apical views rather than dedicated left atrial views
Initiation of cardioprotective therapy was not standardized and may have influenced subsequent cardiac function

Cite This Study

Kaya et al. (2026) conducted a cohort in Breast cancer treated with anthracycline-based chemotherapy (n=50). Multimodal surveillance strategy (LVGLS, LASr, and hs-TnI) vs. Single-parameter assessment (LVGLS alone) was evaluated on Early anthracycline-induced cardiotoxicity (> 10% reduction in LVEF to < 53% at 1 month) (AUC 0.979, 95% CI 0.954-1.000, p=0.003). A multimodal surveillance strategy integrating left ventricular global longitudinal strain, left atrial reservoir strain, and high-sensitivity troponin I demonstrated excellent discrimination for early anthracycline-induced cardiotoxicity (AUC 0.979).

synapsesocial.com/papers/69ddda4de195c95cdefd7bbe https://doi.org/10.1186/s44348-026-00071-y

View Full Paper

Ask AI

Bookmark

April 14, 2026Journal of Cardiovascular ImagingOpen Access

A multimodal approach to early detection of anthracycline-induced cardiotoxicity: complementary roles of left ventricular global longitudinal strain, left atrial reservoir strain, and high-sensitivity troponin I

View Full Paper

Ask AI

Bookmark

Key result

Multimodal surveillance using LVGLS, LASr, and hs-TnI detects early anthracycline-induced cardiotoxicity with AUC ~0.98.

AUC 0.979
95% CI 0.954-1.000
P=0.003
n=50

Why the study?

Anthracycline chemotherapy causes dose-dependent cardiotoxicity, making early identification of subclinical myocardial injury crucial to prevent irreversible dysfunction.

Does a multimodal surveillance strategy integrating LVGLS, LASr, and hs-TnI predict early anthracycline-induced cardiotoxicity in female breast cancer patients?

Population

50 female breast cancer patients receiving anthracycline-based chemotherapy

Comparison

Multimodal surveillance integrating LVGLS, LASr, and hs-TnI vs baseline

Design

Retrospective cohort study

Follow-up

1 month after chemotherapy

Authors

AKAhmet Ferhat Kaya MÖMehmet Özbek

Discussion

Member takes

Overview

May improve early anthracycline cardiotoxicity detection via multimodal surveillance; extends prior evidence but remains hypothesis-generating pending validation.

Key Points

To determine if a multimodal strategy using LVGLS, LASr, and hs-TnI can predict early cardiotoxicity from anthracycline chemotherapy.
Retrospective cohort study with 50 female breast cancer patients
Echocardiography and biomarkers assessed at baseline and one month post-chemotherapy
Cardiotoxicity defined as >10% reduction in LVEF to <53%
Cardiotoxicity occurred in 15 patients (30%)
All measured parameters (LVGLS, LASr, hs-TnI) significantly changed (P < 0.001)
hs-TnI demonstrated the highest ability to discriminate cardiotoxicity (AUC 0.940)

Study Design

Type

Cohort (n=50)

Multicenter

Structured PICO

Does a multimodal surveillance strategy integrating LVGLS, LASr, and hs-TnI predict early anthracycline-induced cardiotoxicity in female breast cancer patients?

Population

50 female breast cancer patients treated with anthracycline-based chemotherapy, mean age 49.3 ± 8.5 years.

Intervention

Outcome

Early anthracycline-induced cardiotoxicity (defined as a > 10% reduction in LVEF to < 53%) at 1 month after chemotherapy.surrogate

Main Result

Effect estimate: AUC 0.979 (95% CI 0.954-1.000)

p-value: p=0.003

Limitations

Small sample size and limited number of outcome events (n = 15) increasing the risk of model overfitting
No external validation cohort was included
Cardiotoxicity was defined based on a single 1-month follow-up echocardiographic assessment without serial confirmation
Follow-up was limited to the early post-chemotherapy period
Left atrial strain was derived from standard left ventricular-focused apical views rather than dedicated left atrial views
Initiation of cardioprotective therapy was not standardized and may have influenced subsequent cardiac function

Cite This Study

synapsesocial.com/papers/69ddda4de195c95cdefd7bbe https://doi.org/10.1186/s44348-026-00071-y

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark